TrialBreast cancer research : BCR2025

Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer.

Alix Devaux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.